While there was no evident change in T cell density during progression to metastatic disease, we did observe a decrease in CD3+, CD8+ and FoxP3+ T cells during chemotherapy, both in the neoadjuvant and palliative setting. The gene discussed is FOXP3; the disease is metastatic neoplasm.